Letteratura scientifica selezionata sul tema "Cer-001"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Indice
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Cer-001".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Cer-001"
Zheng, Kang He, Fleur M. van der Valk, Loek P. Smits, Mara Sandberg, Jean-Louis Dasseux, Rudi Baron, Ronald Barbaras et al. "HDL mimetic CER-001 targets atherosclerotic plaques in patients". Atherosclerosis 251 (agosto 2016): 381–88. http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.038.
Testo completoOssoli, A., A. Strazzella, S. Simonelli, D. Rottoli, M. Abbate, C. M. Zoja, J. L. Dasseux e L. Calabresi. "Remodeling And Catabolism Of Cer-001 In Absence Of Lcat Enzyme". Atherosclerosis 287 (agosto 2019): e107. http://dx.doi.org/10.1016/j.atherosclerosis.2019.06.312.
Testo completoKeyserling, Constance H., Ronald Barbaras, Renee Benghozi e Jean-Louis Dasseux. "Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings". Clinical Drug Investigation 37, n. 5 (17 febbraio 2017): 483–91. http://dx.doi.org/10.1007/s40261-017-0506-3.
Testo completoNicholls, Stephen J., Jordan Andrews, John J. P. Kastelein, Bela Merkely, Steven E. Nissen, Kausik K. Ray, Gregory G. Schwartz et al. "Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial". JAMA Cardiology 3, n. 9 (1 settembre 2018): 815. http://dx.doi.org/10.1001/jamacardio.2018.2121.
Testo completoLi, Chen, Pan Pan Wu e Kun Zhang. "Preparaitve Separation and Purification of Cordycepin from Cultured Cordyceps militaris Using Cation Exchange Resin". Advanced Materials Research 550-553 (luglio 2012): 1773–78. http://dx.doi.org/10.4028/www.scientific.net/amr.550-553.1773.
Testo completoFlores-Peña, Yolanda, María Eugenia Pérez-Campa, Hermelinda Ávila-Alpirez, Juana Mercedes Gutiérrez-Valverde e Gustavo Gutiérrez-Sánchez. "Depressive symptoms, maternal feeding styles, and preschool child’s body weight". Salud mental 44, n. 6 (2 dicembre 2021): 261–66. http://dx.doi.org/10.17711/sm.0185-3325.2021.034.
Testo completoFaguer, Stanislas, Magali Colombat, Dominique Chauveau, Pauline Bernadet-Monrozies, Audrey Beq, Audrey Delas, Vincent Soler et al. "Administration of the High-Density Lipoprotein Mimetic CER-001 for Inherited Lecithin–Cholesterol Acyltransferase Deficiency". Annals of Internal Medicine 174, n. 7 (luglio 2021): 1022–25. http://dx.doi.org/10.7326/l20-1300.
Testo completoNicholls, Stephen J., Jordan Andrews, John Jp Kastelein, Bela Merkely, Steven E. Nissen, Kausik Ray, Gregory G. Schwartz et al. "CARAT: will infusing a pre-beta high-density lipoprotein mimetic (CER-001) regress coronary atherosclerosis?" Atherosclerosis 263 (agosto 2017): e10. http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.060.
Testo completoOssoli, A., A. Strazzella, D. Rottoli, C. Zanchi, M. Locatelli, C. Zoja, S. Simonelli et al. "CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency". Atherosclerosis 331 (agosto 2021): e39. http://dx.doi.org/10.1016/j.atherosclerosis.2021.06.112.
Testo completoFaguer, S., M. Colombat, D. Chauveau, P. Bernadet, A. Delas, V. Soler, I. Labadens, A. Huart e J. Schanstra. "Place du mimétique HDL CER-001 dans la glomérulopathie secondaire aux déficits en lécithine-cholestérol acyltransférase (LCAT)". Néphrologie & Thérapeutique 17, n. 5 (settembre 2021): 317–18. http://dx.doi.org/10.1016/j.nephro.2021.07.182.
Testo completoTesi sul tema "Cer-001"
Begue, Floran. "Lipoprotéines de haute densité (HDL). Implications diagnostiques et thérapeutiques au cours de la COVID 19". Electronic Thesis or Diss., La Réunion, 2024. http://www.theses.fr/2024LARE0002.
Testo completoHigh-density lipoproteins (HDL) are crucial for maintaining good cardiovascular health due to their ability to transport cholesterol from peripheral tissues to the liver for elimination via a "reverse transport of cholesterol” mechanism. Moreover, HDL exhibits several other advantageous properties, including anti-inflammatory, antioxidant, and anti-infectious activities. In inflammatory situations, such as those encountered during viral infections, HDL can undergo both quantitative alterations, with a drop in circulating concentration, and qualitative alterations, such as a change in composition and loss of protective activities. Humanity is still struggling with coronavirus disease (COVID-19), characterized by acute inflammation and responsible for over 6.9 million deaths worldwide to date. The aim of my thesis was to characterize the quantitative and qualitative changes in HDL during COVID-19, to identify specific biomarkers of the changes found in HDL, and to conduct a therapeutic trial of HDL mimetic supplementation during this disease. Quantification of circulating lipoproteins in the plasma of patients with severe COVID 19 shows a significant decrease in HDL and other lipoproteins, which may be predictive biomarkers of disease severity. Analysis of lipoprotein distribution shows a pro-atherogenic profile, with the presence of small, dense low-density lipoproteins (LDL) in the plasmas of patients with severe COVID-19. Qualitative mass spectrometry analysis of the composition of both HDL and LDL showed an increased presence of proteins from the acute phase of inflammation, to the detriment of the apoprotein part of these lipoproteins when isolated from the plasma of COVID-19 patients. When tested on human endothelial cells from primary culture, HDL demonstrated a significant alteration in their anti-apoptotic and anti-inflammatory properties when purified from the plasma of COVID-19 patients. Finally, the anti-inflammatory properties of recombinant HDL injections were demonstrated in a patient admitted to intensive care with a severe form of COVID-19. In conclusion, my thesis work provides some new insights into lipoprotein modifications during infectious disease, in this case COVID-19. It also opens up promising prospects for research into the use of HDL both as a biomarker of inflammatory disease severity and as a means of therapeutic control